Core Viewpoint - BioVaxys Technology Corp. and Adiverna LLC have entered into a Research Agreement to develop mRNA-based vaccines for companion animals, marking a significant advancement in veterinary healthcare [1][2]. Group 1: Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on novel immunotherapies based on the DPX™ immune-educating technology platform [9]. - Adiverna LLC is dedicated to advancing veterinary medicine through cutting-edge mRNA-based vaccines and therapies, utilizing proprietary technology to enhance the health of companion animals [11][14]. Group 2: Technology and Innovation - Adiverna employs artificial intelligence to design and optimize mRNA sequences for vaccines tailored for companion animals, a groundbreaking approach as no mRNA vaccines are currently approved for these animals [2][12]. - The BioVaxys DPX platform offers a novel non-systemic mechanism of action for vaccine delivery, enhancing immune response by targeting lymphatic nodes without releasing active ingredients at the injection site [3][4]. Group 3: Market Potential - The global rabies veterinary vaccines market is valued at approximately US$785 million in 2024 and is projected to reach around US$1.1 billion by 2030, growing at a CAGR of 5.8% [7]. - The broader dog vaccine market, which includes canine leptospirosis vaccines, was valued at approximately US$2.10 billion in 2025, while the feline vaccines sector is projected to grow from US$1.77 billion in 2025 to US$3.28 billion by 2034 [7]. Group 4: Advantages of mRNA Vaccines - DPX-formulated mRNA vaccines are expected to provide longer-lasting immunity with fewer doses compared to traditional vaccines, along with rapid and durable neutralizing antibody responses [4][5]. - Adiverna's mRNA platform has significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses [2][4].

Core Achievements in 2025 - The company achieved significant milestones in 2025, focusing on R&D innovation, regulatory approvals, and operational excellence to enhance competitiveness in the veterinary vaccine market [4][5] - Four new patents were granted, and ten new patent applications were filed to sustain the innovation pipeline [5] - The company received two National Category I and one National Category III New Veterinary Drug Registration Certificates, enhancing its product portfolio and market position [5] - Seven new product approval licenses were secured, expanding offerings across swine, poultry, cattle, and sheep [5] - The company established the Jilin Province Animal Vaccine Science and Technology Innovation Center with government funding of RMB800,000 [5] - The flagship product "Zhengyuanzhen" was awarded "Excellent Vaccine Product of the Year" at the 2025 China Swine Industry Glory List [6] International Market Expansion - The company submitted registration materials for poultry vaccines in Egypt, Pakistan, and Vietnam, with approvals expected in 2026 [12] - A dedicated swine health business unit was established to enhance customer engagement and support key accounts [12] Production Capabilities and Digital Transformation - The company upgraded its bacterial inactivated vaccine production line to include bacterial culture subunit vaccine capabilities [12] - Key production processes were computerized to improve manufacturing efficiency and product quality consistency [12] Strategic Outlook for 2026 - The company plans to deepen strategic customer engagement and strengthen its product portfolio with solution-based marketing [13][14] - A merger and acquisition strategy will focus on the companion animal sector to broaden the product portfolio and enhance capabilities [17] - The company aims to solidify market leadership of its core product and advance the development of new vaccines [18]